Kin schreef op 4 maart 2016 10:39:
Tigenix submitted the marketing authorisation application (MAA) to EMA for
Cx601 for the treatment of complex perianal fistulas in Crohn's disease
The filing of the dossier to gain European approval comes in-line with
previous guidelines. Tigenix reconfirmed its ambition to gain approval in 2017
allowing to bring the product to the market in 2H17.